| Date | Title | Description | Source |
| 28.03.2024 | Syndax Announces Completion of Enrollment in AUGMENT-101 Piv... | – Topline data expected in 4Q24 could support sNDA filing in 1H25 –
– Revumenib has the potential to... | salamancap... |
| 26.03.2024 | Syndax Announces FDA Priority Review of NDA for Revumenib fo... | – PDUFA action date set for September 26, 2024 –
– NDA being reviewed under FDA's RTOR program –
WAL... | salamancap... |
| 02.10.2023 | Syndax’s leukemia drug succeeds in pivotal study | Syndax Pharmaceuticals’ treatment for a genetically defined form of advanced leukemia met its goal i... | statnews.c... |
| 07.04.2023 | Syndax Pharmaceuticals Reports Inducement Grants Under NASDA... | WALTHAM, Mass., April 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. SNDX, a clinical-stage bi... | einpresswi... |
| 11.12.2022 | Syndax Announces Positive Updated Data from Phase 1 Portion ... | - 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2A... | einpresswi... |
| 07.12.2022 | Syndax Announces Pricing of $150 Million Public Offering of ... | WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the &... | einpresswi... |
| 04.02.2022 | Syndax Pharmaceuticals Announces Transition of Michael A. Me... | WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the &... | marketscre... |
| 20.01.2022 | Syndax Announces Presentation at B. Riley Securities' 2022 O... | WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the ... | marketscre... |
| 07.01.2022 | Syndax Announces Presentation at 40th Annual J.P. Morgan Hea... | WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the &... | marketscre... |
| 22.12.2021 | Syndax Announces Orphan Drug Designation Granted to SNDX-561... | WALTHAM, Mass., Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the ... | marketscre... |
| 16.12.2021 | Syndax Announces Pricing of $75.3 Million Public Offering | WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the ... | marketscre... |
| 24.11.2021 | Patient death prompts clinical trial pause for Kura Oncology... | A patient in an early-stage clinical trial evaluating a Kura Oncology cancer drug has died, leading ... | medcitynew... |
| 31.01.2020 | Syndax Announces $35.0 Million Offering of Common Stock and ... | – Offering led by premier life sciences investors including BVF, Boxer Capital and AI Life Sciences ... | aislingcap... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 04.01.2016 | Biotech Startups Hit the Ground Running, With Six Filing IPO... | If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, ... | techcrunch... |
| 25.08.2015 | Syndax Pharmaceuticals Grabs $80M |
WALTHAM, MA, Syndax Pharmaceuticals announced today that it has completed an $80 million Series C ... | vcnewsdail... |
| 24.08.2015 | Syndax Pharmaceuticals Closes $80M in Series C Funding | Syndax Pharmaceuticals Inc., a Waltham, Massachusetts-based biopharmaceutical company focused on tre... | finsmes.co... |
| 24.08.2015 | Sporty Monday: FanDuel Keeps Buying and the LA Dodgers Start... | If you're a sports fan, today's funding roundup should make you happy beyond belief. The Los Angeles... | tech.co/ne... |
| 24.08.2015 | Syndax Raises $80 Million in Series C Financing | | domainvc.c... |
| 24.08.2015 | Syndax Raises $80 Million in Series C Financing | - | mpmcapital... |
| 17.04.2015 | Stealth San Diego startup Metacrine raising $33M. Are we rea... | Evans, Metacrine’s founder, is a lauded gene expression researcher at the Salk Institute who has a n... | medcitynew... |
| 22.09.2014 | Despite IPO plans, Syndax raises another $5 million for epig... | The company is collaborating with the National Cancer Institute, and has several other Phase II and ... | medcitynew... |
| 27.08.2013 | Syndax snags $26.6M round for Phase III breast cancer study | Waltham, MA-based Syndax Pharmaceuticals took a big step to the threshold of a key pivotal study for... | fiercebiot... |
| 27.08.2013 | Syndax Pharmaceuticals Inks $26.6M Series B |
WALTHAM, MA, Firm developing epigenetic therapies for treatment-resistant cancers, today announced... | vcnewsdail... |
| 27.08.2013 | Syndax Pharmaceuticals Secures $26.6 Million Series B Financ... | | domainvc.c... |
| 27.08.2013 | Syndax Pharmaceuticals Secures $26.6M Series B Financing | Syndax Pharmaceuticals Inc., a Waltham, MA-based developer of epigenetic therapies for treatment-res... | finsmes.co... |
| 15.08.2010 | Syndax Pharmaceuticals Raises $6M | Syndax Pharmaceuticals, Inc., a Waltham, MA-based clinical-stage epigenetics oncology company, has i... | finsmes.co... |
| - | Stealth San Diego startup Metacrine raising $33M. Are we rea... | An interesting new San Diego biotech – Metacrine – is in the works.
CFO Trisha Millican said the com... | medcitynew... |
| - | Patient death prompts clinical trial pause for Kura Oncology... | A patient in an early-stage clinical trial evaluating a Kura Oncology cancer drug has died, leading ... | medcitynew... |
| - | Despite IPO plans, Syndax raises another $5 million for epig... | A company in the burgeoning field of epigenetics has raised about $5 million in debt financing, righ... | medcitynew... |